About Citius Pharmaceuticals
Citius Pharmaceuticals is a publicly listed company based in Cranford (United States) founded in 2007. Drugs for infectious and gastrointestinal diseases are developed. The company has 23 employees. Its focus areas include Diversified Pharmaceuticals. Its legal entity is CITIUS PHARMACEUTICALS, INC.
Company details
Citius Pharmaceuticals was founded in 2007 and is headquartered in Cranford, United States. Focus is placed on the development of pharmaceutical products targeting infectious and gastrointestinal diseases. Operations involve research and drug innovation within the biotechnology sector, with activities conducted primarily in the U.S. market. The companys domain, citiuspharma.com, supports its online presence for stakeholders.
- Headquarters Cranford, United States
- Employees 23
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website citiuspharma.com
- Social X
- Legal Name Citius Pharmaceuticals, Inc.
- Net Profit-$37.43 M (USD)4.36as on Sep 30, 2025
- EBITDA-$38.31 M (USD)8.32as on Sep 30, 2025
- Latest Funding Round$20M (USD), Post-IPO
Jan 2021
- Employee Count23
Funding Insights of Citius Pharmaceuticals
- Total Rounds 9
- Last Round Post-IPO — $20M
- First Round $3M
(Mar 2016)
All 9 funding rounds of Citius Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $20M | Post-IPO | – | – | – |
| May 2020 | $220,588 | Post-IPO | – | – | – |
| Apr 2019 | $5.3M | Post-IPO | – | – | – |
| Aug 2018 | $10M | Post-IPO | – | – | – |
| Mar 2018 | $83,688 | Post-IPO | – | – | – |
| Dec 2017 | $40,011 | Post-IPO | – | – | – |
| Feb 2017 | $549,900 | Post-IPO | – | – | – |
| May 2016 | $4.1M | Post-IPO | – | – | – |
| Mar 2016 | $3M | Post-IPO | – | – | – |
People of Citius Pharmaceuticals
10 people are tracked at Citius Pharmaceuticals (8 in leadership, 1 in board & advisors, 1 in team); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
Amber Svardal | National Director, MSL | Leadership |
Jaime Bartushak | CFO & Chief Business Officer | Leadership |
Leonard Mazur | Co-Founder, CEO & Chairman | Leadership |
Myron S. Czuczman | Chief Medical Officer & EVP | Leadership |
Paul Sowyrda | VP, Business Development & Market Intelligence | Leadership |
Ilanit Allen | VP, Investor Relations | Leadership |
John Westman | VP, Project Management | Leadership |
Alan Lader | SVP, Head of Clinical Operations & Quality Assurance | Leadership |
Myron Holubiak | Co-Founder & Executive Vice Chairman | Board & advisors |
Jay Wadekar | SVP, Business Strategy | Team |
Complete people profiles for Citius Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Citius Pharmaceuticals
Citius Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CTXR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Jul 2017
- Listed onNASDAQ: CTXR
- Listed entityCitius Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS17322U3068
- Share price$0.48 (-3.41% on the day) · 2026-10-13
- Market capitalisation$13.1M
- EPS (diluted, trailing year)$-2.11
- Volume (last session)201,103
Financials of Citius Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$37.4M | -$38.3M | |
| 2024 | -$39.1M | -$41.8M | |
| 2023 | -$32.5M | -$36.5M | |
| 2022 | -$33.6M | -$33.1M | |
| 2021 | -$23.1M | -$23.4M |
Detailed financial statements for Citius Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Citius Pharmaceuticals
4 dated milestones of Citius Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Citius Pharmaceuticals is founded.
- Funding First funding round of $3.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Web traffic of Citius Pharmaceuticals
The website of Citius Pharmaceuticals (citiuspharma.com) receives about 4.2K visits a month and ranks #4,074,276 among all websites worldwide, #5,101 in Biotechnology and Pharmaceuticals.
- Monthly visits4.2K
▼ 9.3% vs previous month
- Unique visitors2K
per month
- Global rank#4,074,276
among all websites
- Category rank#5,101
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.5
- Average visit30 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Citius Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| appliedclinicaltrialsonline.com | 100% | #747,616 | View details | ||
| healthtree.org | 63% | 105.7K | #375,183 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Citius Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Citius Pharmaceuticals
Complete news archive for Citius Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Citius Pharmaceuticals
Citius Pharmaceuticals was founded in 2007 and raised its 1st funding round 9 years after it was founded.
Citius Pharmaceuticals is headquartered in Cranford, United States. It is registered at Cranford, New Jersey, United States.
Citius Pharmaceuticals has 23 employees.
Citius Pharmaceuticals was founded in 2007 and is headquartered in Cranford, United States. Focus is placed on the development of pharmaceutical products targeting infectious and gastrointestinal diseases. Operations involve research and drug innovation within the biotechnology sector, with activities conducted primarily in the U.S. market. The companys domain, citiuspharma.com, supports its online presence for stakeholders.
Yes, Citius Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CTXR.
Citius Pharmaceuticals operates through Citius Pharmaceuticals, Inc..